SCHEMBL309301

SCHEMBL309301

CC1(C)OCc2ccc(C=O)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 3/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 2/20 0.35
POLB P06746 2/20 0.35
PTK2B Q14289 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PTGS2 P35354 1/20 0.34
PGR P06401 4/20 0.33
CYP2A6 P11509 3/20 0.33
ALDH1A3 P47895 2/20 0.33
KCNJ1 P48048 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29790958 0.79 ALDH1A1 (0.38) ALDH1A1HSD17B10TDP1MEN1KMT2A
SCHEMBL30340334 0.75 ALDH1A1 (0.42) ALDH1A1HSD17B10TDP1TSHRMEN1
SCHEMBL6156507 0.75 ALDH1A1 (0.42) ALDH1A1HSD17B10TDP1TSHRMEN1
SCHEMBL16172610 0.73 SLC5A1 (0.34) TDP1MEN1KMT2AMAPTKDM4E
SCHEMBL23463196 0.72 PGR (0.33) PGR
SCHEMBL9727613 0.72 OPRM1 (0.41) ALDH1A1
SCHEMBL30648685 0.72 CA9 (0.38) ALDH1A1TDP1MEN1KMT2AMAPT
SCHEMBL30648842 0.72 KDM1A (0.36) ALDH1A1PGR
SCHEMBL26640593 0.72 CA9 (0.38) ALDH1A1TDP1MEN1KMT2AMAPT
SCHEMBL6156513 0.71 ALDH1A1 (0.42) ALDH1A1HSD17B10TDP1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093406-B2 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2012-01-10 US disclosed
CN-102076678-A Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG 2011-05-25 CN disclosed
EP-2303857-A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS Novartis AG (CH) 2011-04-06 EP disclosed
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2010-03-04 US disclosed
WO-2010003976-A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors BACE2, BACE1, APP ALDH1A1 2566/4885HSD17B10 2690/4885TDP1 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.